Capsaicin
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Capsaicin
Description:
Capsaicin ((E) -Capsaicin), an active component of chili peppers, is a TRPV1 agonist. Capsaicin has pain-relieving, antioxidant, anti-inflammatory, anti-cancer effects[1][2].Product Name Alternative:
(E) -CapsaicinUNSPSC:
12352005Hazard Statement:
H302, H315, H318Target:
Apoptosis; Autophagy; Endogenous Metabolite; TRP ChannelType:
Natural ProductsRelated Pathways:
Apoptosis; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal SignalingApplications:
Cancer-programmed cell deathField of Research:
Cancer; Infection; Neurological Disease; Inflammation/ImmunologyAssay Protocol:
https://www.medchemexpress.com/Capsaicin.htmlPurity:
99.88Solubility:
DMSO : 100 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)Smiles:
CC(C)/C=C/CCCCC(NCC1=CC=C(O)C(OC)=C1)=OMolecular Formula:
C18H27NO3Molecular Weight:
305.41Precautions:
H302, H315, H318References & Citations:
[1]McNamara FN, et al. Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1) . Br J Pharmacol. 2005 Mar;144 (6) :781-90.|[2]Shin YH, et al. The Effect of Capsaicin on Salivary Gland Dysfunction. Molecules. 2016 Jun 25;21 (7) .|[3]Anandakumar P, et al. Capsaicin provokes apoptosis and restricts benzo (a) pyrene induced lung tumorigenesis in Swiss albino mice. Int Immunopharmacol. 2013 Jun 6;17 (2) :254-259.|[4]Nah JJ, et al. Effect of ginsenosides, active components of ginseng, on capsaicin-induced pain-related behavior. Neuropharmacology. 2000 Aug 23;39 (11) :2180-4.|[5]Joshi SK, et al Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience. 2006 Dec 1;143 (2) :587-96.|[6]Pelissier T, et al. The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine. Pain. 2002 Mar;96 (1-2) :81-7.|[7]Matsuda H, et al. Roles of capsaicin-sensitive sensory nerves, endogenous nitric oxide, sulfhydryls, and prostaglandins in gastroprotection by momordin Ic, an oleanolic acid oligoglycoside, on ethanol-induced gastric mucosal lesions in rats. Life Sci. 1999;65 (2) :PL27-32.|[8]Demirbilek S, et al. Small-dose capsaicin reduces systemic inflammatory responses in septic rats. Anesth Analg. 2004 Nov;99 (5) :1501-1507.|[9]Friedman JR, et al. Anticancer Activity of Natural and Synthetic Capsaicin Analogs. J Pharmacol Exp Ther. 2018 Mar;364 (3) :462-473.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C (Powder, protect from light)Scientific Category:
Natural ProductsClinical Information:
LaunchedCitation 01:
ACS Omega. 2025 Aug 21;10 (34) :39192-39202.|Acta Pharmacol Sin. 2023 Apr;44 (4) :766-779.|Acta Pharmacol Sin. 2024 Jun;45 (6) :1160-1174.|Adv Mater. 2022 Mar;34 (11) :e2108435.|Adv Sci (Weinh) . 2025 Sep 15:e10102.|Am J Pathol. 2023 May;193 (5) :548-557.|Antioxidants (Basel) . 2022 May 20;11 (5) :1003.|bioRxiv. 2024 Jan 7.|BMC Med. 2024 Nov 4;22 (1) :504.|Brain Res Bull. 2024 Jun 1:211:110950.|Cancer Cell Int. 2024 Aug 28;24 (1) :300.|Cancer Cell Int. 2025 Oct 3;25 (1) :328.|Cell Biol Int. 2024 May 5.|Cell Discov. 2024 Nov 12;10 (1) :114.|Cell Metab. 2022 Dec 6;34 (12) :1999-2017.e10.|Cell Rep. 2023 Dec 2;42 (12) :113522.|Cell. 2024 Jun 6;187 (12) :2935-2951.e19.|Cell. 2025 Oct 24:S0092-8674 (25) 01129-8.|ChemMedChem. 2025 Jan 23:e202400913.|Cytotechnology. 2025 Aug;77 (4) :141.|EMBO J. 2025 Aug;44 (15) :4222-4251.|Eur J Pharmacol. 2024 Aug 16:176909.|Exp Cell Res. 2023 Dec 15;433 (2) :113856.|Exp Ther Med. 2023 May 15;26 (1) :318.|FASEB J. 2024 May 31;38 (10) :e23661.|FASEB J. 2025 Jul 15;39 (13) :e70778.|FASEB J. 2025 May 31;39 (10) :e70657.|Front Oncol. 2022 Mar 25;12:773654.|Front Pharmacol. 2025 Sep 29:16:1671461.|Inflammopharmacology. 2025 Jan;33 (1) :257-267.|Int Immunopharmacol. 2025 May 13:158:114807.|Int J Nanomedicine. 2024 Jan 3:19:73-90.|Invest Ophthalmol Vis Sci. 2025 Jun 2;66 (6) :28.|J Biol Chem. 2022 May;298 (5) :101847.|J Cardiovasc Pharmacol. 2022 Sep 1;80 (3) :430-441.|J Cardiovasc Transl Res. 2024 Dec;17 (6) :1415-1426.|J Funct Foods. 2023 Nov , 110, 105823.|J Inflamm Res. 2024 Apr 11:17:2245-2256.|J Inflamm Res. 2024 Jan 9:17:153-170.|J Inflamm Res. 2024 Jul 2:17:4257-4275.|J Med Chem. 2025 Nov 27;68 (22) :24011-24023.|J Mol Neurosci. 2024 Aug 20;74 (3) :79.|J Mol Neurosci. 2025 Oct 14;75 (4) :138.|J Neurochem. 2025 Jan;169 (1) :e16281.|J Neurosci. 2024 Jul 17:e0740242024.|J Periodontal Res. 2024 Aug;59 (4) :798-811.|J Vis Exp. 2025 Oct 3: (224) .|Microbiol Spectr. 2022 Dec 21;10 (6) :e0241022.|Mol Med Rep. 2024 Jul;30 (1) :110.|Mol Med Rep. 2025 Dec;32 (6) :322.|Mol Med. 2024 Sep 12;30 (1) :148.|Nat Commun. 2023 Apr 17;14 (1) :2182.|Neurotherapeutics.2024 May 21:e00377.|Ocul Surf. 2024 Oct:34:406-414.|Open Biol. 2025 Mar;15 (3) :240226.|Patent. US20250127769A1.|Pathol Res Pract. 2025 Sep:273:156143.|Pharmaceuticals (Basel) . 2024 Dec 15;17 (12) :1694.|Phytomedicine. 2022 Mar 21;100:154067.|Phytomedicine. 2025 Oct:146:157130.|Phytother Res. 2022 Feb;36 (2) :938-950.|Phytother Res. 2024 Sep;38 (9) :4386-4405.|Res Sq. 2024 Sep 22.|Res Sq. 2025 Oct 8.|Research Square Preprint. 2023 Oct 13.|Research Square Preprint. 2024 Sep 03.|Research Square Print. 2022 Jun.|SSRN. 2023 Sep 11.|Tissue Cell. 2025 Nov 21:99:103243.|Toxicol Appl Pharmacol. 2026 Jan:506:117655.|Neurosci Bull. 2025 Oct 30.CAS Number:
[404-86-4]
